Novo Nordisk's Moat Is Deeper Than You Think

2025-07-22 10:03:54 ET

Investment Thesis

Despite a YTD drop of 25%, Novo Nordisk (NVO) remains a dominant force in the meteoric GLP-1 space for diabetes and obesity with assistance from 65% obesity drugs sales growth and a franchise of patients amounting to 46 million. Insurpassable clinical evidence, high-priced product portfolio, and expanding global infrastructure form a solid foundation for free cash flow generation. Despite compounded substitutes' pressure on near-term sentiment, regulatory shift and strategic initiatives position Novo for share recovery with ongoing compounding through one of the strongest seculars in healthcare....

Read the full article on Seeking Alpha

For further details see: